An evaluation of the cardiotoxicity of imatinib mesylate

被引：52

作者：

Ribeiro, Antonio Luiz ^{[1
,2
]}

Marcolino, Milena Soriano ^{[1
]}

Bittencourt, Henrique N. S. ^{[1
,3
]}

Barbosa, Marcia M. ^{[4
]}

Nunes, Maria do Carmo P. ^{[1
,2
]}

Xavier, Vitor Fonseca ^{[1
]}

Clementino, NeIrna C. D. ^{[1
,3
]}

机构：

[1] Univ Fed Minas Gerais, Hosp Clin, Sch Med, BR-30130100 Belo Horizonte, MG, Brazil

[2] Univ Fed Minas Gerais, Hosp Clin, Serv Cardiol, BR-30130100 Belo Horizonte, MG, Brazil

[3] Univ Fed Minas Gerais, Hosp Clin, Hematol Serv, BR-30130100 Belo Horizonte, MG, Brazil

[4] Hosp Socor, BR-30110075 Belo Horizonte, MG, Brazil

来源：

LEUKEMIA RESEARCH | 2008年 / 32卷 / 12期

关键词：

Imatinib; Cardiotoxicity; Chronic myeloid leukaemia; Ventricular function; BNP;

D O I：

10.1016/j.leukres.2008.03.020

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We studied 103 consecutive patients with chronic myeloid leukaemia on treatment with imatinib (IM) and 57 patients with chronic myeloproliferative disorders not treated with IM in order to evaluate its cardiotoxicity. There was no statistical difference regarding cardiac symptoms and signs, BNP levels and echocardiographic measurements for IM and control groups, except for peripheral oedema, more frequent in the IM group. Four patients in the IM group presented a BNP level >100 pg/ml, one of them with depressed LVEF. IM was not related to systematic deterioration of cardiac function, but there is still a possibility of isolated cases of cardiotoxicity. (C) 2008 Elsevier Ltd. All rights reserved.

引用

页码：1809 / 1814

页数：6

共 50 条

[1] Cardiotoxicity of the cancer therapeutic agent imatinib mesylate
Risto Kerkelä
Luanda Grazette
Rinat Yacobi
Cezar Iliescu
Richard Patten
Cara Beahm
Brian Walters
Sergei Shevtsov
Stéphanie Pesant
Fred J Clubb
Anthony Rosenzweig
Robert N Salomon
Richard A Van Etten
Joseph Alroy
Jean-Bernard Durand
Thomas Force
[J]. Nature Medicine, 2006, 12 : 908 - 916
[2] Cardiotoxicity of imatinib mesylate: a rare adverse effect?
Marcolino, M. S.
Clementino, N. C. D.
Bittencourt, H. N. S.
Barbosa, M. M.
Nunes, M. C. P.
Silva, M. H. C. R.
Ribeiro, A. L. P.
[J]. EUROPEAN HEART JOURNAL, 2009, 30 : 287 - 288
[3] Cardiotoxicity of the cancer therapeutic agent imatinib mesylate
Kerkela, Risto
Grazette, Luanda
Yacobi, Rinat
Iliescu, Cezar
Patten, Richard
Beahm, Cara
Walters, Brian
Shevtsov, Sergei
Pesant, Stephanie
Clubb, Fred J.
Rosenzweig, Anthony
Salomon, Robert N.
Van Etten, Richard A.
Alroy, Joseph
Durand, Jean-Bernard
Force, Thomas
[J]. NATURE MEDICINE, 2006, 12 (08) : 908 - 916
[4] Ageing is a risk factor in imatinib mesylate cardiotoxicity
Maharsy, Wael
Aries, Anne
Mansour, Omar
Komati, Hiba
Nemer, Mona
[J]. EUROPEAN JOURNAL OF HEART FAILURE, 2014, 16 (04) : 367 - 376
[5] In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'
Rosti, Gianantonio
Martinelli, Giovanni
Baccarani, Michele
[J]. NATURE MEDICINE, 2007, 13 (01) : 15 - 15
[6] In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'
Alan Hatfield
Samantha Owen
Paul Richard Pilot
[J]. Nature Medicine, 2007, 13 (1) : 13 - 13
[7] In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'
Carlo Gambacorti
Lucia Tornaghi
Anna Franceschino
Rocco Piazza
Gianmarco Corneo
Enrico Pogliani
[J]. Nature Medicine, 2007, 13 (1) : 13 - 14
[8] In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'
Gianantonio Rosti
Giovanni Martinelli
Michele Baccarani
[J]. Nature Medicine, 2007, 13 : 15 - 15
[9] In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'
Ehab Atallah
Hagop Kantarjian
Jorge Cortes
[J]. Nature Medicine, 2007, 13 (1) : 14 - 14
[10] In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'
Thomas Force
[J]. Nature Medicine, 2007, 13 (1) : 15 - 16

← 1 2 3 4 5 →